The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats

Behavioural Pharmacology

Volumn 18, Issue 7, 2007, Pages 601-608

  Wooters, Thomas E ^a   Bardo, Michael T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Clorgyline; Drug discrimination; Monoamine oxidase inhibitor; Nicotine; Pargyline; Phenelzine; Rat

Indexed keywords

CLORGYLINE; NICOTINE; PARGYLINE; PHENELZINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG INHIBITION; DRUG SELECTIVITY; MALE; NONHUMAN; RAT; STIMULUS RESPONSE;

ANIMALS; CLORGYLINE; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ISOENZYMES; MALE; MONOAMINE OXIDASE INHIBITORS; NICOTINE; NICOTINIC AGONISTS; PARGYLINE; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION;

EID: 34948868828     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282eff0d5     Document Type: Article

References (63)

1. Andree TH, Clarke DE (1982). Characteristics and specificity of phenelzine and benserazide as inhibitors of benzylamine oxidase and monoamine oxidase. Biochem Pharmacol 31:825-830.
2. Baldessarini RJ (2006). Drug therapy of depression and anxiety disorders. In: Brunto L, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; pp. 429-460.
3. Balster RL (1991). Drug abuse potential evaluation in animals. Br J Addict 86:1549-1558.
4. Bardo MT, Bevins RA, Klebaur JE, Crooks PA, Dwoskin LP (1997). (-)-Nornicotine partially substitutes for ( + )-amphetamine in a drug discrimination paradigm in rats. Pharmacol Biochem Behav 58:1083-1087.
5. Bardo MT, Green TA, Crooks PA, Dwoskin LP (1999). Nornicotine is self-administered intravenously by rats. Psychopharmacology 146:290-296.
6. Batman AM, Munzar P, Beardsley PM (2005). Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists. Psychopharmacology 179:393-401.
7. Belluzzi JD, Wang R, Leslie FM (2005). Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 30:705-172.
8. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, et al. (2001). Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515-530.
9. Corrigall WA, Coen KM (1989). Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 99:473-478.
10. Corrigall WA, Coen KM (1991). Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 104:171-176.
11. Corrigall WA, Franklin KB, Coen KM, Clarke PB (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285-289.
12. Corrigall WA, Coen KM, Adamson KL (1994). Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653:278-284.
13. Crooks PA, Dwoskin LP (1997). Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54:743-753.
14. Desai RI, Barber DJ, Terry P (1999). Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine. Behav Pharmacol 10:647-656.
15. Desai RI, Barber DJ, Terry P (2003). Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology 167:335-343.
16. Donny EC, Caggiula AR, Knopf S, Brown C (1995). Nicotine self-administration in rats. Psychopharmacology 122:390-394.
17. Fowler CJ, Mantle TJ, Tipton KF (1982). The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, L-deprenyl and pargyline. Biochem Pharmacol 31:3555-3561.
18. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. (1996a). Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733-736.
19. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. (1996b). Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 93:14065-14069.
20. Fowler JS, Logan J, Wang GJ, Volkow ND (2003). Monoamine oxidase and cigarette smoking. Neurotoxicology 24:75-82.
21. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ (2006). Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharm 17:151-159.
22. Ghosheh OA, Dwoskin LP, Li WK, Crooks PA (1999). Residence times and half-lives of nicotine metabolites in brain after acute peripheral administration of [2′-(14)C] nicotine. Drug Metab Dispos 27:1448-1455.
23. Ghosheh OA, Dwoskin LP, Miller DK, Crooks PA (2001). Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′-(14)C] nicotine. Drug Metab Dispos 29:645-651.
24. Glassman AH, Koob GF (1996). Psychoactive smoke. Nature 379:677-678.
25. Goldberg SR, Risner ME, Stolerman IP, Reavill C, Garcha HS (1989). Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology 97:295-302.
26. Green TA, Crooks PA, Bardo MT, Dwoskin LP (2001). Contributory role for nornicotine in nicotine neuropharmacology: nornicotine-evoked [3H] dopamine overflow from rat nucleus accumbens slices. Biochem Pharmacol 62:1597-1603.
27. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, Stinus L (2005). Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 25:8593-8800.
28. Guillem K, Vouillac C, Azar MR, Parsons LH, Koob GF, Cador M, Stinus L (2006). Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 24:3532-3540.
29. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004). Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology 175:134-142.
30. Henningfield JE, Fant RV (1999). Tobacco use as drug addiction: the scientific foundation. Nicotine Tob Res 2(1 Suppl):S31-S35.
31. Ilani T, Lamensdorf I, Finberg JPM (2000). Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea pig. Br J Pharmacol 130:1992-1998.
32. Kozlowski LT (1982). The determinants of tobacco use: cigarettes in the context of other forms of tobacco use. Can J Pub Health 73:236-241.
33. Kozlowski LT, Henningfield JE, Brigham J (2001). Cigarettes, nicotine and health: A biobehavioral approach. Thousand Oaks, California: Sage Publications.
34. Le Foll B, Goldberg SR (2005). Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci 26:287-293.
35. Lewis A, Miller JH, Lea RA (2006). Monoamine oxidase and tobacco dependence. Neurotoxicology 28:182-195.
36. Mansvelder HD, Keath JR, McGehee DS (2002). Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 33:905-919.
37. Manzardo AM, Stein L, Belluzzi JD (2002). Rats prefer cocaine over nicotine in a two-lever self-administration choice test. Brain Res 924:10-19.
38. Matthies H, Popov N (1966). Various effects of monoamine oxidase inhibitors under conditions of complete monoamine oxidase inhibition on the serotonin, dopamine and noradrenalline levels in the rat brain. Acta Biol Med Ger 17:488-497.
39. McKim RH, Calverly DG, Dewhurst WG, Baker GB (1983). Regional concentrations of cerebral amines: effects of tranylcypromine and phenelzine. Prog Neuropsychopharmacol Biol Psychiatry 7:783-786.
40. Murphy DL, Lipper S, Slater S, Shiling D (1979). Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Psychopharmacology 62:129-132.
41. Nestler EJ, Hyman SE, Malenka RC (2001). Molecular neuropharmacology: A foundation for clinical neuroscience. New York: McGraw-Hill.
42. Nishi K, Muck-Seler D, Hasegawa S, Watanabe A, Diksic M (2006). Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: an autoradiographic study. Brain Res Bull 70:368-377.
43. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983). The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322:198-202.
44. O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, et al. (2007). Extended access to nicotine self-administration leads to dependence: circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320:180-193.
45. Parent MB, Master S, Kashlub S, Baker GB (2002). Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular γ-aminobutyric acid levels in the striatum. Biochem Pharmacol 63:57-64.
46. Perkins KA, Grobe JE, Caggiula A, Wilson AS, Stiller RL (1997). Acute reinforcing effects of low-dose nicotine nasal spray in humans. Pharmacol Biochem Behav 56:235-241.
47. Perkins KA, Donny E, Caggiula AR (1999). Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1:301-315.
48. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO (2006). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570-584.
49. Quarta D, Naylor CG, Stolerman IP (2007). The serotonin2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology 193:391-402.
50. Rose JE, Corrigall WA (1997). Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology 130:28-40.
51. Rose JE, Levin ED (1991). Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br J Addict 86:605-609.
52. Rose JE, Behm FM, Ramsey C, Ritchie JC Jr (2001). Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 3:383-390.
53. Shoaib M, Zubaran C, Stolerman IP (2000). Antagonism of stimulus properties of nicotinic by dihydro-β-erythroidine. Psychopharmacology 149:140-146.
54. Stolerman IP (1993). Drug discrimination. In: van Haaren F, editor. Methods in behavioral pharmacology. Amsterdam: Elsevier Science Publishers; pp. 217-244.
55. Todd KG, Baker GB (1995). GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Dis 35:125-129.
56. Villegier AS, Blanc G, Glowinski J, Tassin JP (2003). Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidase inhibitors. Pharmacol Biochem Behav 76:267-274.
57. Villegier AS, Salomon L, Blanc G, Godeheu G, Glowinski J, Tassin JP (2006a). Irreversible blockade of monoamine oxidase reveals the critical role of 5-HT transmission in locomotor response induced by nicotine in mice. Eur J Neurosci 24:1359-1365.
58. Villegier AS, Salomon L, Granon S, Changeux JP, Belluzzi JD, Leslie FM, Tassin JP (2006b). Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology 31:1704-1713.
59. Wiesbeck GA, Wodarz N, Weijers HG, Dursteler-MacFarland KM, Wurst FM, Boening J (2006). A functional polymorphism in the promoter region of the monoamine oxidase A gene is associated with the cigarette smoking quantity in alcohol-dependent heavy smokers. Neuropsychobiology 53:181-185.
60. Winer BJ (1971). Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill.
61. Young R, Bondareva T, Wesolowska A, Young S, Glennon RA (2006). Effect of the 5-HT(6) serotonin antagonist MS-245 on the actions of (-)nicotine. Pharmacol Biochem Behav 85:170-177.
62. Yu PH, Davis BA (1999). Inversion of selectivity of N-substituted propargylamine monoamine oxidase inhibitors following structural modifications to quaternary salts. Int J Biochem Cell Biol 31:1391-1397.
63. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM (2001). Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897-902.